SUPPLEMENTAL MATERIALS IN PDF FILE BELOW
Supplemental Appendix. Search Strategy for OVID MEDLINE and Epub Ahead of Print, In-Process, In-Data Review, & Other Non-Indexed Citations and Daily <January 2022 to May23, 2023>
Supplemental Table 1. Additional Characteristics of the Included RCTs
Supplemental Table 2. Risk of Bias Assessment for the Included Randomized Controlled Trials
Supplemental Table 3. Study Quality Assessment for the Included Real-World Studies
Supplemental Table 4. Grading of the Evidence for the Outcomes from Randomized Controlled
Trials (RCTs) among adults with laboratory-confirmed mild/moderately severe COVID-19
(RCTs)
Supplemental Figure 1. Forest plot of nirmatrelvir/ritonavir vs no treatment/placebo for reducing worsening severity among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 2. Forest plot of nirmatrelvir/ritonavir vs no treatment/placebo for viral clearance among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 3. Forest plot of nirmatrelvir/ritonavir vs no treatment/placebo for adverse events among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 4. Forest plot of nirmatrelvir/ritonavir vs no treatment/placebo for serious adverse events among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 5. Forest plot of nirmatrelvir/ritonavir vs no treatment/placebo against all-cause mortality among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 6. Trial sequential analysis of nirmatrelvir/ritonavir vs no treatment/placebo for worsening COVID-19 severity among adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 7. Trial sequential analysis of nirmatrelvir/ritonavir vs no treatment/placebo for viral clearance in adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 8. Trial sequential analysis of nirmatrelvir/ritonavir vs no treatment/placebo for adverse events in adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 9. Trial sequential analysis of nirmatrelvir/ritonavir vs no treatment/placebo for serious adverse events in adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)
Supplemental Figure 10. Trial sequential analysis of nirmatrelvir/ritonavir vs no treatment/placebo for reducing all-case mortality in adults with laboratory-confirmed mild/moderately severe COVID-19 (RCTs)